Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2007

View Archived Issues

Variation Biotechnologies raises Series A financing

Preclinical characterization of sergliflozin, a novel selective SGLT2 inhibitor

Poniard and Scripps Research Institute to discover FAK inhibitors

Icagen updates sodium channel programs

Scynexis earns preclinical milestone payment from Merck collaboration

AstraZeneca and Bristol-Myers Squibb collaborate on type 2 diabetes compounds

MultiCell's anticancer combination therapy prevents disease recurrence

Biomedical Research Models licenses Neuralstem compounds in diabetes

Valeant and Metabasis close pradefovir licensing deal with Schering-Plough

CytRx establishes new RNAi subsidiary, RXi Pharmaceuticals

Droxidopa reduces fall in orthostatic systolic blood pressure

Astellas terminates agreement on carperitide for acute heart failure

Progress in phase I study of anticancer compound ECO-4601

Valeant licenses Canadian rights to Xyrem in cataplexy

BioInvent and Genentech collaborate on cardiovascular candidate BI-204

Stimuvax begins phase III study

FDA outlines issues regarding planned phase I study of ReN-001 stem cell therapy

Metastatic pancreatic cancer patients show clinical responses to talabostat therapy

Sativex shows utility in peripheral neuropathic pain

Promising preclinical results with raloxifene-derived selective estrogen receptor modulator

Mycamine launched in 100 mg vial format

Somatuline Autogel NDA accepted for filing

Novel TAFIa inhibitor profiled at Berlex

Recent sanofi-aventis patents report novel therapeutic agents for arrhythmia

Novel treatment options for HIV infection reported in recent patent literature

Recent Gruenenthal patent discloses new analgesic agents